Veracyte Inc.

Company Overview

Business Model: Veracyte, Inc. is a global diagnostics company focused on empowering clinicians with high-value insights for cancer diagnosis and treatment. The company's high-performing tests aim to guide diagnostic, prognostic, and predictive treatment decisions, helping patients avoid unnecessary procedures, accelerate time to appropriate treatment, and improve outcomes. Veracyte, Inc. operates through two complementary models: offering laboratory developed tests (LDTs) in the United States via its centralized CLIA-certified laboratories in South San Francisco, California; San Diego, California; and Austin, Texas (supported by cytopathology expertise); and providing in vitro diagnostic (IVD) tests to international markets through distribution to local laboratories and hospitals. The majority of current revenue is derived from sales of its Decipher Prostate and Afirma tests.

Market Position: Veracyte, Inc. holds a leading position with its portfolio of comprehensive molecular diagnostic tests, emphasizing an individualized approach to cancer care. The Veracyte Diagnostics Platform integrates broad genomic and clinical data, deep bioinformatics, and artificial intelligence (AI) capabilities to generate evidence for durable reimbursement and guideline inclusion. Decipher Prostate is positioned as the only genomic test utilized across the full continuum of prostate cancer, supported by over 115 peer-reviewed studies and inclusion in the 2026 NCCN Clinical Practice Guidelines in Oncology for Prostate Cancer. The Afirma Genomic Sequencing Classifier (GSC) is a key offering for thyroid cancer, with strong clinical validation (meta-analysis showing 97% sensitivity, 88% specificity, 99% NPV) and inclusion in leading practice guidelines. Decipher Bladder is the first genomic test covered by Medicare for bladder cancer. The company's competitive advantages stem from its platform, scientific excellence, extensive clinical evidence, key opinion leader (KOL) support, and established payer coverage policies.

Recent Strategic Developments:

• C2i Genomics, Inc. Acquisition (2024): Veracyte, Inc. acquired C2i Genomics, Inc., an MRD (minimal residual disease) detection company, adding whole-genome MRD capabilities to its diagnostics platform. This acquisition aims to expand the company's role across the cancer care continuum, from early decision support to treatment monitoring and recurrence detection.
• TrueMRD Launch (Expected H1 2026): The company anticipates launching its first TrueMRD application as a muscle-invasive bladder cancer (MIBC) MRD test in the first half of 2026, leveraging its urology commercial channel.
• Prosigna LDT Launch (Expected 2026): Veracyte, Inc. plans to launch the Prosigna Breast Cancer Assay as an LDT for the U.S. market in 2026 to serve more breast cancer patients.
• Illumina, Inc. Partnership (2023): A multi-year agreement with Illumina, Inc. was announced to develop and offer molecular tests, including the Prosigna Breast Cancer Assay, as decentralized IVD tests on Illumina, Inc.'s NextSeq 550Dx NGS instrument in international markets (Canada, Europe, Middle East, Asia Pacific, Latin America).
• Decipher Prostate IVD Development: The company is developing the Decipher Prostate test as a quantitative polymerase chain reaction-based (qPCR-based) test for launch as a decentralized IVD outside the United States.
• Veracyte SAS Divestiture (August 2025): Veracyte, Inc. completed the divestiture of the contract manufacturing portion of its French subsidiary, Veracyte SAS, to Helio Diagnostics SAS, ceasing its controlling interest in Veracyte SAS.

Geographic Footprint: Veracyte, Inc. is headquartered in South San Francisco, California, with additional operations in San Diego, California; Austin, Texas; and Haifa, Israel. In 2025, the United States accounted for $496,598 thousand of total revenue, while international markets contributed $20,547 thousand. Substantially all of the company's long-lived assets were located in the United States as of December 31, 2025.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 70.1%
• Operating Margin: 11.2%
• Net Margin: 12.8%

Investment in Growth:

• R&D Expenditure: $70,814 thousand (13.7% of revenue)
• Capital Expenditures: $9,677 thousand (purchases of property, plant and equipment)
• Strategic Investments: The 2024 acquisition of C2i Genomics, Inc. for $100.2 million, comprising $73.3 million in common stock, $0.8 million in replacement stock options, and $17.2 million in contingent consideration. The company continues to invest in its innovation engine, early-stage products (including MRD tests), required clinical studies, and the development of current IVD tests.

Business Segment Analysis

Veracyte, Inc. operates as a single reporting segment focused on the development and commercialization of diagnostic products and services.

Testing Revenue (Primary Business Activity)

Financial Performance:

• Revenue: $493,154 thousand (+18% YoY)
• Total Diagnostic tests reported: 169,714 (+19% YoY)
• Key Growth Drivers: The increase was primarily driven by a $66.7 million increase in Decipher Prostate revenue and a $13.7 million increase in Afirma revenue. Decipher Prostate volume grew by 27% to approximately 102,000 tests, and Afirma volume grew by 11% to approximately 67,700 tests. This growth was supported by increased staffing and infrastructure build-out, partially offset by lab efficiencies.

Product Portfolio:

• Decipher Prostate Genomic Classifiers: Utilizes whole-transcriptome analysis and machine learning on prostate tissue to assess tumor biology and estimate the risk of metastatic disease. It informs clinical decision-making across the prostate cancer continuum, including active surveillance, treatment selection, and post-prostatectomy management. The test is supported by over 115 peer-reviewed studies and is included in the 2026 NCCN Clinical Practice Guidelines. Medicare and commercial payers covering over 215 million enrollees reimburse the test, with metastatic indication covered by Medicare since October 2024.
• Afirma Genomic Sequencing Classifier (GSC): Designed for thyroid cancer, this test uses whole-transcriptome RNA sequencing and machine learning on FNA biopsy specimens to identify benign nodules, helping patients avoid unnecessary surgery. It also provides gene mutation information for suspicious or malignant nodules. Clinical validation data show high sensitivity (97%) and negative predictive value (99%) in real-world settings. The test is included in leading practice guidelines and covered for over 275 million Medicare and commercial enrollees.
• Decipher Bladder Genomic Classifier: Measures the molecular profile of bladder cancer from tumor specimens using gene expression analysis. It reports molecular subtypes to identify patients at higher risk of upstaging and those who may benefit most from neoadjuvant therapy. It is the first genomic test for bladder cancer covered by Medicare.
• Percepta Nasal Swab Test: A noninvasive test under clinical study for early lung cancer detection. It detects genomic changes in nasal passage samples from current and former smokers, aiming to help physicians accurately determine lung cancer risk and avoid unnecessary invasive procedures.
• TrueMRD Platform: Acquired through C2i Genomics, Inc., this whole-genome, AI-powered minimal residual disease (MRD) platform is designed to track tumor progression, treatment effectiveness, and disease recurrence from small blood samples (3-4 ml blood or 1-2 ml plasma) with a two-week turnaround time. The first application is expected in MIBC.

Product Revenue

Financial Performance:

• Revenue: $14,327 thousand (+5% YoY)
• Product tests sold: 9,814 (flat YoY)
• Key Growth Drivers: The increase in product revenue was primarily driven by an improved average selling price per test.

Product Portfolio:

• Prosigna Breast Cancer Assay: A clinically validated prognostic assay for post-menopausal women with early-stage, hormone receptor positive breast cancer. It analyzes 46 genes (PAM50 signature) to provide a risk-of-recurrence score, aiding in chemotherapy decisions. The test is offered as an IVD test on the nCounter Analysis System globally (CE-IVD marked) and is expected to be offered as an LDT in the U.S. in 2026. It is recommended in major U.S. and international guidelines and reimbursed in several European countries, Canada, and Israel.

Biopharmaceutical and Other Revenue

Financial Performance:

• Revenue: $9,664 thousand (-27% YoY)
• Key Growth Drivers: The decrease was due to reduced business conducted in France following the restructuring proceedings affecting Veracyte SAS in August 2025.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: The company did not report a formal share repurchase program. Tax payments related to the vesting of restricted stock units amounted to $18,304 thousand in 2025.
• Dividend Payments: Veracyte, Inc. has never declared or paid dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain future earnings for business growth.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: No specific future capital return commitments were disclosed.

Balance Sheet Position:

• Cash and Equivalents: $362,578 thousand (as of December 31, 2025)
• Total Short-term Investments: $50,311 thousand (as of December 31, 2025)
• Total Cash, Equivalents and Short-term Investments: $412,889 thousand (as of December 31, 2025)
• Total Debt: The company's primary debt-like obligations are operating lease liabilities, totaling $39,654 thousand (present value of future lease payments) as of December 31, 2025.
• Net Cash Position: Approximately $373,235 thousand (Total Cash, Equivalents and Short-term Investments minus Total Operating Lease Liabilities).
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Operating lease liabilities extend to March 2040, with total future minimum lease payments of $72,805 thousand.

Cash Flow Generation:

• Operating Cash Flow: $136,307 thousand (for the year ended December 31, 2025)
• Free Cash Flow: Approximately $126,630 thousand (Operating Cash Flow minus Capital Expenditures of $9,677 thousand).
• Cash Conversion Metrics: Cash received is generally collected within 12 months of the test billing date.

Operational Excellence

Production & Service Model: Veracyte, Inc. operates its CLIA-certified laboratories in the U.S. with a focus on operational excellence, measuring performance by lab-processing turnaround time, failure rates, and deviation vs. control. This systematic approach aims to deliver optimal outcomes for patients and physicians while improving cost efficiency and scalability. For international markets, the company distributes IVD tests for local performance in laboratories and hospitals. The TrueMRD platform, acquired through C2i Genomics, Inc., is designed for rapid, efficient whole-genome, AI-powered minimal residual disease detection from small blood samples.

Supply Chain Architecture: Key Suppliers & Partners:

• Reagents & Equipment: Relies on sole suppliers for critical reagents, equipment, and other materials essential for its CLIA tests and Prosigna test/service kits.
• Kit Components: Purchases components for sample collection kits from sole-source suppliers.
• External Assembly/Distribution: Utilizes external providers for the assembly and distribution of sample collection kits.
• Cytopathology Services: Depends on sole service providers, such as Thyroid Cytopathology Partners, for professional diagnoses on thyroid fine needle aspiration.
• IVD Platform Components: Relies on NanoString Technologies, Inc. (now Bruker Spatial Biology) for specific components and raw materials for the Prosigna test and nCounter Analysis System service kits.
• Illumina, Inc.: Strategic partner for developing and offering molecular tests as decentralized IVD tests on their NextSeq 550Dx NGS instrument.
• Helio Diagnostics SAS: Contract manufacturing partner for certain IVD products following the divestiture of Veracyte SAS's contract manufacturing operations.

Facility Network:

• Manufacturing/Laboratory: Key production and testing facilities are located in South San Francisco, California (Afirma testing), San Diego, California (urology tests), and Austin, Texas (Afirma FNA sample storage).
• Research & Development: R&D operations are conducted in Haifa, Israel (acquired through C2i Genomics, Inc.).
• Distribution: The company's IVD tests are distributed to laboratories and hospitals globally.

Operational Metrics:

• Total Diagnostic tests reported: 169,714 (2025).
• Product tests sold: 9,814 (2025).

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: An internal sales force of approximately 120 representatives is organized by business unit in the U.S., targeting thyroid cancer and urologic cancer physicians. Outside the U.S., country managers and sales teams target laboratories and breast cancer oncologists for Prosigna sales.
• Channel Partners: Utilizes distributors for the Prosigna IVD test kit across Europe, Asia, and Latin America.
• Digital Platforms: An online portal facilitates physician ordering and tracking of Afirma GSC tests and result downloads.

Customer Portfolio: Enterprise Customers:

• Biopharmaceutical Companies: Engages in partnerships with biopharmaceutical companies, providing data from CLIA tests to offer insights into disease genetics.
• Hospitals and Laboratories: Direct sales of IVD tests are made to hospital and laboratory customers internationally.
• Customer Concentration (2025 Revenue):
  • Medicare: 33% of testing revenue.
  • UnitedHealthcare Group: 14% of testing revenue.
  • Private commercial payers (including Medicare Advantage): 47% of testing revenue.
  • Medicare Advantage (paid by commercial payers): 18% of testing revenue.
  • Medicaid: 1% of testing revenue.
• Customer Concentration (2025 Accounts Receivable):
  • Medicare: 20% of total accounts receivable.
  • UnitedHealthcare Group: 14% of total accounts receivable.

Geographic Revenue Distribution:

• United States: $496,598 thousand (96.0% of total revenue in 2025).
• International: $20,547 thousand (4.0% of total revenue in 2025).
• Growth Markets: The company is actively expanding its IVD offerings in global markets, particularly in Europe, and developing new indications for its MRD platform.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The diagnostics market is highly competitive, characterized by a growing understanding of biomarkers for therapy selection, response, and early screening, leading to increased genomic profiling services. Rapid technological advancements, especially in genomic information, necessitate continuous innovation to keep pace with evolving standards of care.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Thyroid Cancer (Afirma): Interpace Diagnostics Group, Inc. and ThyroSeq (marketed by Sonic Healthcare Limited).
• Prostate Cancer (Decipher Prostate): Myriad Genetics, Inc. and MDxHealth, SA. Traditional pathology methods and AI-powered image analysis companies like ArteraAI also pose competitive threats.
• Bladder Cancer (Decipher Bladder): No direct genomic testing competitor for its specific intended use population is currently known, but DNA mutational analysis and traditional clinical methods are in use.
• Breast Cancer (Prosigna): Exact Sciences Corporation (holds a substantial market share), Myriad Genetics, Inc., and Agendia, Inc.
• Minimal Residual Disease (MRD): Natera, Inc. is identified as a primary competitor for MIBC MRD. Other potential competitors for future indications include Guardant Health, Inc., Exact Sciences Corporation, Personalis, Myriad Genetics, Inc., Neogenomics, Inc., Quest Diagnostics, Billion-To-One, Caris Life Sciences, and TempusAI, Inc.
• General Commercial Laboratories: Large commercial laboratories such as Laboratory Corporation of America Holdings, Quest Diagnostics, and Sonic Healthcare USA.
• Diagnostic Product Developers: Companies like Thermo Fisher Scientific Inc., Roche Diagnostics (a division of Roche Holding Ltd), Siemens AG, and Qiagen N.V.

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions (e.g., using alternative samples like blood, urine, or sputum, or tumor-naive approaches for MRD) are emerging. Competitors may also develop their own versions of Veracyte, Inc.'s solutions in international markets where intellectual property rights are not recognized.

Competitive Response Strategy: Veracyte, Inc. aims to maintain its competitive advantage by leveraging its Veracyte Diagnostics Platform, scientific and technological excellence, extensive clinical evidence, strong KOL support, and established payer coverage policies. The company's strategy includes utilizing its specialist channels to engage early in the cancer care continuum and continuously innovating and expanding its product offerings.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The company's financial results are highly dependent on sales of Decipher Prostate and Afirma tests. There is a risk that payers may cease or reduce reimbursement, delay payments, or recoup past payments, particularly given the reliance on a few key payers (Medicare, UnitedHealthcare Group). Physician and patient adoption may be limited by lack of guideline inclusion, changes in clinical practice, or increased patient costs. The integration of acquired businesses, such as C2i Genomics, Inc., carries risks related to technical integration, undisclosed liabilities, and personnel retention. International expansion faces challenges in regulatory approvals and differing standards of care. The rapid pace of technological advancements in diagnostics poses a risk of obsolescence if the company cannot continuously innovate. Macroeconomic factors, including inflation, volatile interest rates, foreign exchange fluctuations, and geopolitical conflicts (e.g., Middle East), could adversely impact business and financial results.

Operational & Execution Risks

Supply Chain Vulnerabilities: Veracyte, Inc. relies on sole suppliers for critical reagents, equipment, and materials for its CLIA tests and IVD kits, as well as sole service providers for cytopathology diagnoses. Any disruption from these suppliers or providers could significantly impact test processing, product delivery, and customer relationships. Inefficient inventory management, including forecasting demand and managing expiration dates, could adversely affect operations. The company faces challenges in managing future growth, including scaling testing capacity, expanding customer service, and recruiting skilled personnel. Errors or defects in products or services, including lab processes, software, or raw materials, could harm reputation and lead to product liability claims. Issues related to the use of AI and machine learning in its offerings, such as technical flaws or ethical concerns, could also adversely affect the business.

Financial & Regulatory Risks

Market & Financial Risks: Despite recent profitability, the company has incurred losses in the past and may not sustain profitability, especially with ongoing inflationary pressures. Billing for diagnostic tests is complex, time-consuming, and expensive, with risks of denials, audits, and long collection cycles. Reliance on third-party providers for claims transmission introduces risks of delays. The company may need to raise additional capital in the future, which may not be available on acceptable terms or could dilute stockholders. Fluctuations in the effective tax rate are possible due to changes in revenue mix, valuation allowances, and tax law changes (e.g., OBBBA). Impairment of goodwill or other intangible assets could materially affect operating results. Changes in financial accounting standards or incorrect estimates in critical accounting policies could lead to unexpected financial reporting fluctuations.

Regulatory & Compliance Risks: The company is subject to extensive federal (CLIA, FDA, HIPAA, Stark Law, Anti-kickback Statute, False Claims Act, PAMA, No Surprises Act) and state (California, New York, Texas licensing, privacy laws) regulations. The FDA's historical enforcement discretion for LDTs is uncertain, and future tests or modifications may require costly and time-consuming premarket review. Improper labeling of "research use only" (RUO) or "investigational use only" (IUO) products could lead to enforcement actions. International IVD products are subject to foreign regulatory requirements, including the EU IVDR and UK regulations, which are complex and evolving. Compliance with data privacy laws (HIPAA, CCPA/CPRA, GDPR, PIPL, Israeli laws) is increasingly complex and costly. The company is also exposed to risks related to the corporate practice of medicine, self-referral prohibitions, anti-kickback laws, and other fraud and abuse statutes.

Geopolitical & External Risks

Geopolitical Exposure: International business operations, including those in Haifa, Israel (acquired through C2i Genomics, Inc.), expose the company to risks from regional conflicts, political instability, and trade restrictions. The ongoing conflict in the Middle East could disrupt operations, impact employees, and affect the global economy. Catastrophic events such as pandemics, war, terrorism, earthquakes, or power outages could damage facilities and disrupt operations. The company is also exposed to foreign currency exchange rate fluctuations.

Innovation & Technology Leadership

Research & Development Focus: Veracyte, Inc.'s R&D efforts are centered on its Veracyte Diagnostics Platform, which leverages broad genomic and clinical data, deep bioinformatics, and AI capabilities. The company employs a whole-transcriptome approach for its diagnostic, prognostic, and predictive tests and has expanded into whole-genome minimal residual disease (MRD) detection through the C2i Genomics, Inc. acquisition. Key innovation pipeline initiatives include the TrueMRD platform (with a first application in MIBC), the launch of Prosigna as an LDT in the U.S., the global expansion of IVD products (including Decipher Prostate as a qPCR-based IVD), and the development of novel tests like the Percepta Nasal Swab for lung cancer detection, based on "field of injury" science.

Intellectual Property Portfolio: The company relies on a combination of patents, copyrights, trademarks, trade secrets, and contractual restrictions to protect its proprietary technologies. Its issued patents expire between 2027 and 2040, and it actively files additional patent applications. Veracyte, Inc. holds registered trademarks for its key products and company names in the U.S. and internationally, with a pending trademark for "TrueMRD." Trade secrets are protected through confidentiality and invention assignment agreements with employees and consultants. The company is actively involved in enforcing its intellectual property rights, as evidenced by a patent infringement lawsuit against Sonic Healthcare USA, Inc.

Technology Partnerships: Veracyte, Inc. has strategic alliances to enhance its technology and market reach. It has a multi-year agreement with Illumina, Inc. to develop and offer molecular tests as decentralized IVD tests on the NextSeq 550Dx NGS instrument. The company also holds an exclusive worldwide license for clinical IVD test use of the nCounter Analysis System, relying on NanoString Technologies, Inc. (now Bruker Spatial Biology) for related components and materials.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company's success is dependent on its executive management team and highly skilled employees. It acknowledges the competitive nature of attracting and retaining talent in the life sciences industry, including scientists, medical/clinical staff, and salespeople. The company utilizes equity awards to incentivize and retain employees.

Board Composition: The board of directors, in coordination with the Audit Committee, oversees the company's risk management program, including cybersecurity. The board is undergoing a declassification process, with directors now subject to one-year terms upon election, starting from the 2024 annual meeting.

Human Capital Strategy

Workforce Composition: As of December 31, 2025, Veracyte, Inc. had 755 employees. Its workforce is distributed across its U.S. and Israeli operations, comprising highly skilled scientists for R&D, medical and clinical staff for studies and physician/payer education, and qualified sales and specialized administrative personnel.

Talent Management: Acquisition & Retention: The company operates in a highly competitive industry for qualified personnel. It relies on a strong culture and equity awards to attract and retain talent. Employee Value Proposition: Veracyte, Inc. emphasizes a strong culture that fosters innovation, collaboration, and mutual respect. It was certified as a Great Place to Work in both the United States and Israel in 2025, based on employee feedback. The company's core values are: "We are stronger together; We seek a better way; We care deeply; and We make it happen."

Environmental & Social Impact

Environmental Commitments: Veracyte, Inc.'s operations involve the use of regulated hazardous materials and biohazardous waste, subject to federal, state, and local environmental and safety laws. The company relies on licensed service providers for waste disposal. Historically, the cost of environmental compliance has not materially impacted operations, and no significant expenditures are anticipated for 2026. Recent California climate bills regarding greenhouse gas emissions and climate-related financial risks may impose future disclosure requirements.

Social Impact Initiatives: The company's core mission to provide high-value diagnostic insights for cancer care directly contributes to social well-being by helping patients avoid unnecessary procedures, accelerating appropriate treatment, and improving outcomes.

Business Cyclicality & Seasonality

Demand Patterns: The company's revenue is subject to seasonal trends, influenced by factors such as the number of workdays per period, timing of industry conferences, and when patient deductibles are typically met. Sales are also sensitive to physician ordering patterns, reimbursement policies, and customer budgets, which can vary significantly and unexpectedly.

Planning & Forecasting: Forecasting customer demand is challenging due to limited historical experience with direct sales of molecular diagnostics tests and products. Inaccurate forecasting could negatively impact the company's ability to meet demand and adversely affect operating results.

Regulatory Environment & Compliance

Regulatory Framework: Veracyte, Inc. operates under a complex regulatory landscape. In the U.S., its CLIA-certified laboratories are subject to federal CLIA regulations and state licensing requirements (e.g., California, New York, Texas), including test-specific approvals. While the FDA has historically exercised enforcement discretion over LDTs, the regulatory environment remains uncertain, with potential for future legislation or increased FDA oversight. The Prosigna test is FDA-cleared. Internationally, IVD products are subject to diverse regulatory requirements, including the EU IVDR (which replaced the IVDD in May 2022 and imposes stricter conformity assessment and post-market surveillance) and UK medical device regulations. Companion diagnostics are subject to specific regulatory pathways in both the U.S. and EU.

Trade & Export Controls: The company is subject to FDC Act requirements for medical device exports and foreign government import requirements. Geopolitical risks, including sanctions and trade restrictions, could also impact operations.

Legal Proceedings: Veracyte, Inc. is not currently a party to any material legal proceedings, with the exception of a patent infringement lawsuit filed in May 2025 against Sonic Healthcare USA, Inc. concerning thyroid nodule molecular testing. The jury trial for this case is scheduled for January 25, 2027.

Tax Strategy & Considerations

Tax Profile: Veracyte, Inc. is subject to income taxes in the U.S. and various foreign jurisdictions. The company recorded an income tax provision of $1.8 million in 2025. As of December 31, 2025, it had significant net operating loss (NOL) carryforwards for federal ($561.9 million), California ($113.3 million), other state ($298.4 million), and Canadian ($65.7 million) income tax purposes. Federal NOLs incurred after 2017 carry forward indefinitely, while others begin to expire between 2028 and 2036. The company also holds R&D credit carryforwards. A full valuation allowance is maintained against net deferred tax assets due to uncertainty regarding their realization. The One Big Beautiful Bill Act (OBBBA), signed in July 2025, impacts tax provisions, including the reinstatement of 100% bonus depreciation and immediate expensing of domestic R&D costs, with effects reflected in the 2025 financial statements.

Insurance & Risk Transfer

Risk Management Framework: Veracyte, Inc. maintains cybersecurity risk insurance coverage to mitigate financial exposure from potential cybersecurity breaches. Additionally, it holds product liability and errors and omissions insurance, as well as insurance for property damage and business disruption from catastrophic events, though coverage limits and future availability are subject to uncertainty.